Behrad Derakhshan
Corporate Officer/Principal chez EDGEWISE THERAPEUTICS, INC.
Fortune : 128 045 $ au 31/03/2024
Profil
Behrad Derakhshan is currently the Director at Innoskel SASU and the Chief Business Officer at Edgewise Therapeutics, Inc. He previously worked as the Director at Alexion Pharmaceuticals, Inc. from 2015 to 2017, as the Associate Director at Dymedex Consulting LLC from 2012 to 2015, as the Head-Business Development at Therachon AG from 2017 to 2019, and as the Chief Business Officer at VectivBio AG from 2019 to 2020.
Dr. Derakhshan received his undergraduate degree from the University of Surrey and his doctorate from Weill Cornell Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 09/02/2024 | 7 020 ( 0,01% ) | 128 045 $ | 31/03/2024 |
Postes actifs de Behrad Derakhshan
| Sociétés | Poste | Début |
|---|---|---|
| EDGEWISE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/09/2020 |
Innoskel SASU
 Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | Director/Board Member | - |
Anciens postes connus de Behrad Derakhshan
| Sociétés | Poste | Fin |
|---|---|---|
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01/09/2020 |
| Therachon AG | Corporate Officer/Principal | 01/07/2019 |
| ALEXION PHARMACEUTICALS, INC. | Director/Board Member | 01/04/2017 |
Dymedex Consulting LLC
 Dymedex Consulting LLC Miscellaneous Commercial ServicesCommercial Services Dymedex Consulting LLC provides market development consulting services. It specializes in market analysis, strategic consulting and corporate integration. The company was founded in 2007 by Joseph Galatowitsch and Ross Meisner and is headquartered in St. Paul, MN. | Corporate Officer/Principal | 01/01/2015 |
Formation de Behrad Derakhshan
| University of Surrey | Undergraduate Degree |
| Weill Cornell Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EDGEWISE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Dymedex Consulting LLC
Dymedex Consulting LLC Miscellaneous Commercial ServicesCommercial Services Dymedex Consulting LLC provides market development consulting services. It specializes in market analysis, strategic consulting and corporate integration. The company was founded in 2007 by Joseph Galatowitsch and Ross Meisner and is headquartered in St. Paul, MN. | Commercial Services |
| Therachon AG | |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
Innoskel SASU
Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | Health Technology |
